Annexon Inc
ANNX
NASDAQ
Biotechnology
$5.29
USD
+0.03 (+0.57%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $856.08M
Volume 3.0M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-202.67M
TTM
-8.4%
YoY
Operating Cash Flow
$-193.03M
TTM
-23.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 7.6 | 7.3 | 7.6 | 10.3 | 10.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 51.7 | 57.0 | 50.3 | 46.1 | 57.2 |
Operating Income | -51.7 | -57.0 | -50.3 | -46.1 | -57.2 |
EBITDA | -51.2 | -56.5 | -49.7 | -45.5 | -56.7 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 2.6 | 2.1 | 2.0 | 1.9 | 1.9 |
Income Before Income Taxes | -49.2 | -54.9 | -48.3 | -44.1 | -55.3 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -49.2 | -54.9 | -48.3 | -44.1 | -55.3 |
Consolidated Net Income / Loss | -49.2 | -54.9 | -48.3 | -44.1 | -55.3 |
Net Income Attributable to Common Shareholders | -51.0 | -54.9 | -48.3 | -44.1 | -55.3 |
Basic EPS | -$0.34 | -$0.37 | -$0.28 | -$0.23 | -$0.28 |
Diluted EPS | -$0.34 | -$0.37 | -$0.28 | -$0.23 | -$0.28 |
Basic Shares Outstanding | 148.3M | 149.1M | 174.9M | 194.2M | 201.0M |
Diluted Shares Outstanding | 148.3M | 149.1M | 174.9M | 194.2M | 201.0M |